The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies
to the market. To address the demands of the clinical and eventual commercial-scale …

In recent years, microphysiological system (MPS, also known as, organ-on-a-chip or tissue
chip) platforms have emerged with great promise to improve the predictive capacity of …

Iatrogenic tumorigenesis is a major limitation for the use of human induced pluripotent stem
cells (hiPSCs) in hematology. The teratoma risk comes from the persistence of hiPSCs in …

Parkinson's disease (PD) is the second most frequent neurodegenerative disease after
Alzheimer's disease, which is characterized by a low level of dopamine being expressing in …

Over the past decade, enormous progress has been made in the field of induced pluripotent
stem cells (iPSCs). Patients' somatic cells such as skin fibroblasts or blood cells can be used …

Recent advances in genome-editing techniques have made it possible to modify any
desired DNA sequence by employing programmable nucleases. These next-generation …

Stem cell-based regeneration therapy offers new therapeutic options for patients with bone
defects because of significant advances in stem cell research. Although bone marrow …

The immune system is designed to discriminate between self and tumor tissue. Through
genetic recombination, there is fundamentally no limit to the number of tumor antigens that …

Red blood cells and platelets are anucleate blood components indispensable for oxygen
delivery and hemostasis, respectively. Derivation of these blood elements from induced …

Background The in vitro production of mature human red blood cells (RBCs) from induced
pluripotent stem cells (iPSCs) has been the focus of research to meet the high demand for …